정신질환 바이오마커 시장 : 전략적 인사이트와 예측(2026-2031년)

The Global Psychiatric Disorder Biomarkers Market is projected to grow at a CAGR of 7.6% during the forecast period, increasing from USD 2.57 billion in 2026 to USD 4.96 billion by 2035.

The global psychiatric disorder biomarkers market is emerging as a critical segment within the broader neurodiagnostics and precision medicine industry. Psychiatric disorders such as major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, autism spectrum disorder, and attention-deficit hyperactivity disorder (ADHD) continue to impose substantial healthcare and socioeconomic burdens worldwide. Traditionally, psychiatric diagnoses have relied heavily on clinical assessments, symptom evaluations, and patient interviews, creating challenges related to diagnostic accuracy, treatment selection, and disease monitoring.

Biomarkers are increasingly being explored as objective tools that can support diagnosis, prognosis, treatment response prediction, patient stratification, and disease monitoring. Advances in genomics, proteomics, metabolomics, neuroimaging, and digital biomarker technologies are expanding the understanding of psychiatric disease mechanisms and enabling the identification of measurable biological indicators associated with mental health conditions. As healthcare systems increasingly move toward personalized medicine approaches, psychiatric biomarkers are expected to play a vital role in improving clinical outcomes and optimizing treatment strategies.

Market Drivers

Rising Global Burden of Mental Health Disorders

One of the primary drivers of the psychiatric disorder biomarkers market is the increasing prevalence of mental health conditions worldwide. Depression, schizophrenia, bipolar disorder, anxiety disorders, and neurodevelopmental conditions are affecting millions of individuals across both developed and developing economies.

The growing recognition of mental health as a major public health concern is encouraging investments in advanced diagnostic technologies that can facilitate earlier diagnosis, more accurate patient classification, and improved treatment planning.

Increasing Demand for Precision Psychiatry

Healthcare providers are increasingly seeking personalized treatment approaches that can improve therapeutic outcomes while minimizing trial-and-error prescribing practices. Psychiatric biomarkers offer the potential to identify patients who are most likely to respond to specific treatments based on biological characteristics.

The growing adoption of precision medicine concepts within psychiatry is creating substantial demand for biomarker-based diagnostic and monitoring solutions.

Advancements in Omics Technologies

Rapid progress in genomics, transcriptomics, proteomics, metabolomics, and epigenetics is accelerating biomarker discovery across psychiatric disorders. Researchers are increasingly identifying molecular signatures associated with disease susceptibility, progression, and treatment response.

These technological advances are improving the ability to detect biological abnormalities linked to psychiatric conditions and are supporting the development of next-generation diagnostic platforms.

Growing Investment in Neuroscience Research

Governments, academic institutions, pharmaceutical companies, and biotechnology firms are investing heavily in neuroscience and mental health research. Increased funding for psychiatric disease studies is facilitating large-scale biomarker discovery programs and clinical validation efforts.

The growing emphasis on understanding the biological basis of mental illnesses is expected to accelerate biomarker commercialization and clinical adoption.

Market Restraints

Complexity of Psychiatric Disorders

Psychiatric disorders are highly heterogeneous and involve complex interactions among genetic, environmental, neurobiological, and psychosocial factors. Identifying reliable biomarkers that consistently correlate with specific psychiatric conditions remains challenging.

The multifactorial nature of mental illnesses can complicate biomarker validation and clinical implementation.

Limited Clinical Validation

Although numerous biomarker candidates have been identified through research, relatively few have achieved widespread clinical adoption. Extensive validation studies are required to demonstrate diagnostic accuracy, reproducibility, and clinical utility across diverse patient populations.

The lengthy validation process may delay commercialization and market expansion.

Regulatory and Standardization Challenges

Biomarker-based diagnostic tools must comply with rigorous regulatory requirements before entering clinical practice. Variability in testing methodologies, data interpretation standards, and clinical protocols may create barriers to adoption.

Establishing standardized biomarker assessment frameworks remains a critical challenge for industry stakeholders.

Technology and Segment Insights

The global psychiatric disorder biomarkers market can be segmented by biomarker type, disorder type, technology platform, application, end user, and geography.

By biomarker type, the market includes genetic biomarkers, proteomic biomarkers, metabolomic biomarkers, neuroimaging biomarkers, inflammatory biomarkers, epigenetic biomarkers, and digital biomarkers. Genetic and neuroimaging biomarkers represent significant areas of research due to their potential to improve disease characterization and treatment selection.

By disorder type, the market encompasses major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, autism spectrum disorder, ADHD, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), and other psychiatric conditions. Depression and schizophrenia account for major research and commercial opportunities due to their high disease burden and unmet diagnostic needs.

By technology platform, the market includes genomic sequencing, polymerase chain reaction (PCR), next-generation sequencing, mass spectrometry, immunoassays, neuroimaging technologies, bioinformatics platforms, and artificial intelligence-based analytical systems. Advances in data analytics and machine learning are enabling the identification of complex biomarker patterns that may improve diagnostic precision.

By application, the market includes diagnosis, risk assessment, patient stratification, treatment response prediction, disease monitoring, and drug development. Diagnostic applications currently attract significant attention as healthcare providers seek objective tools to support psychiatric evaluations. Biomarkers are also becoming increasingly important in clinical trial design and precision drug development.

By end user, the market serves hospitals, psychiatric clinics, research institutions, academic centers, pharmaceutical companies, biotechnology firms, and diagnostic laboratories. Research institutions and pharmaceutical companies represent major users due to extensive biomarker discovery and validation activities. Healthcare providers are expected to increase adoption as clinically validated solutions become available.

Technological innovation is transforming the market through the integration of artificial intelligence, machine learning, digital health platforms, wearable devices, and real-world data analytics. Digital biomarkers generated from smartphones, wearable sensors, and behavioral monitoring systems are emerging as promising tools for continuous patient assessment and remote mental health monitoring.

Geographically, North America represents a leading market due to advanced healthcare infrastructure, strong neuroscience research capabilities, significant healthcare spending, and increasing mental health awareness. Europe maintains a substantial market share supported by extensive research funding and precision medicine initiatives. Asia-Pacific is expected to experience rapid growth due to expanding healthcare infrastructure, increasing mental health awareness, growing research investments, and rising adoption of advanced diagnostic technologies. Latin America and the Middle East & Africa are also expected to witness gradual market development as healthcare systems strengthen mental health services.

Competitive and Strategic Outlook

The psychiatric disorder biomarkers market is characterized by increasing collaboration among pharmaceutical companies, biotechnology firms, academic institutions, diagnostic developers, and healthcare organizations. Companies are actively pursuing biomarker discovery, validation, and commercialization strategies to establish leadership positions in this evolving field.

Strategic initiatives include research partnerships, clinical collaborations, licensing agreements, mergers and acquisitions, and investments in artificial intelligence-driven biomarker platforms. Organizations are focusing on developing integrated diagnostic solutions that combine molecular, imaging, genetic, and digital biomarkers to improve diagnostic accuracy and clinical utility.

Pharmaceutical companies are also incorporating biomarkers into drug development programs to improve patient selection, enhance clinical trial efficiency, and support personalized treatment approaches. As precision psychiatry continues to advance, biomarker-driven healthcare solutions are expected to become increasingly important across both clinical and research settings.

Conclusion

The global psychiatric disorder biomarkers market is poised for strong growth through 2031, driven by increasing mental health disease burden, growing demand for precision medicine, advancements in omics technologies, and expanding neuroscience research investments. Biomarkers have the potential to transform psychiatric care by providing objective tools for diagnosis, treatment selection, disease monitoring, and drug development. While challenges related to disease complexity, clinical validation, and regulatory requirements remain, ongoing technological innovation and scientific progress are expected to support long-term market expansion and improve mental healthcare outcomes worldwide.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Overview
  • 1.1.1 Definition and Scope of Psychiatric Disorder Biomarkers
  • 1.1.2 Market Evolution and Clinical Significance
  • 1.1.3 Biomarker Categories and Applications
  • 1.1.4 Precision Psychiatry and Biomarker Integration
  • 1.1.5 Key Market Trends
• 1.2 Executive Insights
  • 1.2.1 Key Growth Drivers
  • 1.2.2 Emerging Opportunities
  • 1.2.3 Market Challenges
  • 1.2.4 Strategic Recommendations
• 1.3 Market Snapshot
  • 1.3.1 Current Market Landscape
  • 1.3.2 Competitive Overview
  • 1.3.3 Innovation Highlights

2. Disease & Epidemiology Analysis

• 2.1 Psychiatric Disorders Overview
  • 2.1.1 Disease Classification
  • 2.1.2 Neurobiological Basis of Psychiatric Disorders
  • 2.1.3 Burden of Mental Health Disorders
• 2.2 Epidemiology Analysis
  • 2.2.1 Global Prevalence of Major Depressive Disorder (MDD)
  • 2.2.2 Global Prevalence of Bipolar Disorder
  • 2.2.3 Global Prevalence of Schizophrenia Spectrum Disorders
  • 2.2.4 Global Prevalence of Anxiety Disorders
  • 2.2.5 Global Prevalence of Post-Traumatic Stress Disorder (PTSD)
• 2.3 Disease Subtype Analysis
  • 2.3.1 Treatment-Resistant Depression
  • 2.3.2 Bipolar I Disorder
  • 2.3.3 Bipolar II Disorder
  • 2.3.4 First-Episode Psychosis
  • 2.3.5 Chronic Schizophrenia
  • 2.3.6 Generalized Anxiety Disorder
  • 2.3.7 Major Neuropsychiatric Comorbidities
• 2.4 Patient Journey and Biomarker Integration
  • 2.4.1 Early Detection and Risk Assessment
  • 2.4.2 Differential Diagnosis
  • 2.4.3 Treatment Selection
  • 2.4.4 Disease Monitoring
  • 2.4.5 Relapse Prediction

3. Market Dynamics

• 3.1 Market Drivers
  • 3.1.1 Rising Global Mental Health Burden
  • 3.1.2 Increasing Demand for Objective Psychiatric Diagnostics
  • 3.1.3 Growth of Precision Psychiatry
  • 3.1.4 Expansion of Neuroimaging and Genomic Technologies
  • 3.1.5 Increasing Research Funding for Mental Health Biomarkers
• 3.2 Market Restraints
  • 3.2.1 Limited Biomarker Validation
  • 3.2.2 Disease Heterogeneity
  • 3.2.3 Reimbursement Challenges
  • 3.2.4 Regulatory Complexity
• 3.3 Market Opportunities
  • 3.3.1 AI-Driven Biomarker Discovery
  • 3.3.2 Multi-Omics Psychiatric Profiling
  • 3.3.3 Digital Biomarkers and Remote Monitoring
  • 3.3.4 Companion Diagnostics for Psychiatry
• 3.4 Market Trends
  • 3.4.1 Blood-Based Biomarker Development
  • 3.4.2 Neuroimaging Biomarker Expansion
  • 3.4.3 Pharmacogenomic Testing Adoption
  • 3.4.4 Machine Learning Integration in Psychiatry

4. Commercial & Market Access

• 4.1 Commercialization Landscape
  • 4.1.1 Clinical Adoption Trends
  • 4.1.2 Precision Psychiatry Implementation
  • 4.1.3 Diagnostic Service Models
• 4.2 Reimbursement Analysis
  • 4.2.1 Public Healthcare Coverage
  • 4.2.2 Private Insurance Coverage
  • 4.2.3 Pharmacogenomic Test Reimbursement
• 4.3 Health Economic Assessment
  • 4.3.1 Economic Burden of Psychiatric Disorders
  • 4.3.2 Cost of Diagnostic Delays
  • 4.3.3 Value of Biomarker-Guided Treatment Selection

5. Innovation & Pipeline Landscape

• 5.1 Biomarker Innovation Overview
  • 5.1.1 Diagnostic Biomarkers
  • 5.1.2 Prognostic Biomarkers
  • 5.1.3 Predictive Biomarkers
  • 5.1.4 Monitoring Biomarkers
• 5.2 Biomarker Modality Analysis
  • 5.2.1 Genomic Biomarkers
  • 5.2.2 Pharmacogenomic Biomarkers
  • 5.2.3 Proteomic Biomarkers
  • 5.2.4 Metabolomic Biomarkers
  • 5.2.5 Neuroimaging Biomarkers
  • 5.2.6 Digital Biomarkers
  • 5.2.7 Electrophysiological Biomarkers
• 5.3 Pipeline Landscape by Development Stage
  • 5.3.1 Discovery Stage Programs
  • 5.3.2 Early Clinical Validation Programs
  • 5.3.3 Advanced Clinical Validation Programs
  • 5.3.4 Commercialization-Ready Biomarker Platforms
• 5.4 Innovation Benchmarking
  • 5.4.1 AI-Based Psychiatric Biomarker Platforms
  • 5.4.2 Digital Mental Health Biomarkers
  • 5.4.3 Multi-Omics Platforms
  • 5.4.4 Precision Psychiatry Decision-Support Systems

6. Treatment Landscape

• 6.1 Current Treatment Paradigm
  • 6.1.1 Antidepressant Therapy
  • 6.1.2 Antipsychotic Therapy
  • 6.1.3 Mood Stabilizers
  • 6.1.4 Psychotherapy
  • 6.1.5 Neuromodulation Therapies
• 6.2 Biomarker Applications Across Treatment Pathways
  • 6.2.1 Treatment Selection
  • 6.2.2 Drug Response Prediction
  • 6.2.3 Adverse Event Prediction
  • 6.2.4 Disease Monitoring
  • 6.2.5 Relapse Risk Assessment
• 6.3 Biomarker Utility Benchmarking
  • 6.3.1 Genomic Biomarkers
  • 6.3.2 Neuroimaging Biomarkers
  • 6.3.3 Blood-Based Biomarkers
  • 6.3.4 Digital Biomarkers

7. Market Size & Forecast

• 7.1 Historical Market Assessment
• 7.2 Current Market Analysis
• 7.3 Market Forecast by Biomarker Type
• 7.4 Market Forecast by Application
• 7.5 Market Forecast by End User
• 7.6 Market Forecast by Region
• 7.7 Adoption and Utilization Trends

8. Market Segmentation

• 8.1 By Biomarker Type
  • 8.1.1 Genomic Biomarkers
  • 8.1.2 Pharmacogenomic Biomarkers
  • 8.1.3 Proteomic Biomarkers
  • 8.1.4 Metabolomic Biomarkers
  • 8.1.5 Neuroimaging Biomarkers
  • 8.1.6 Digital Biomarkers
  • 8.1.7 Electrophysiological Biomarkers
• 8.2 By Indication
  • 8.2.1 Major Depressive Disorder
  • 8.2.2 Bipolar Disorder
  • 8.2.3 Schizophrenia Spectrum Disorders
  • 8.2.4 Anxiety Disorders
  • 8.2.5 PTSD
  • 8.2.6 Other Psychiatric Disorders
• 8.3 By End User
  • 8.3.1 Psychiatric Hospitals
  • 8.3.2 Specialty Mental Health Clinics
  • 8.3.3 Diagnostic Laboratories
  • 8.3.4 Academic and Research Institutions

9. Geographical Analysis

• 9.1 North America
  • 9.1.1 Market Size & Growth
  • 9.1.2 Demand Drivers
  • 9.1.3 Regional Regulatory Environment
  • 9.1.4 Competitive Intensity
• 9.2 Europe
  • 9.2.1 Market Size & Growth
  • 9.2.2 Demand Drivers
  • 9.2.3 Regional Regulatory Environment
  • 9.2.4 Competitive Intensity
• 9.3 Asia-Pacific
  • 9.3.1 Market Size & Growth
  • 9.3.2 Demand Drivers
  • 9.3.3 Regional Regulatory Environment
  • 9.3.4 Competitive Intensity
• 9.4 Latin America
  • 9.4.1 Market Size & Growth
  • 9.4.2 Demand Drivers
  • 9.4.3 Regional Regulatory Environment
  • 9.4.4 Competitive Intensity
• 9.5 Middle East & Africa
  • 9.5.1 Market Size & Growth
  • 9.5.2 Demand Drivers
  • 9.5.3 Regional Regulatory Environment
  • 9.5.4 Competitive Intensity

10. Key Countries Analysis

• 10.1 United States
• 10.2 Canada
• 10.3 Germany
• 10.4 United Kingdom
• 10.5 France
• 10.6 Italy
• 10.7 Spain
• 10.8 China
• 10.9 Japan
• 10.10 India
• 10.11 South Korea
• 10.12 Australia
• 10.13 Brazil
• 10.14 Mexico
• 10.15 Saudi Arabia
• 10.16 South Africa

11. Regulatory & Policy Landscape

• 11.1 United States
  • 11.1.1 FDA Diagnostic Regulatory Framework
  • 11.1.2 Pharmacogenomic Testing Oversight
  • 11.1.3 Software as Medical Device (SaMD) Regulations
• 11.2 Europe
  • 11.2.1 IVDR Framework
  • 11.2.2 CE Marking Requirements
  • 11.2.3 Clinical Evidence Requirements
• 11.3 Japan
  • 11.3.1 PMDA Diagnostic Approval Pathways
  • 11.3.2 Precision Medicine Regulations
• 11.4 India
  • 11.4.1 CDSCO Diagnostic Regulations
  • 11.4.2 Market Entry Requirements
• 11.5 China
  • 11.5.1 NMPA Diagnostic Framework
  • 11.5.2 Local Validation Requirements
• 11.6 Reimbursement and HTA Landscape
  • 11.6.1 Health Technology Assessment
  • 11.6.2 Coverage Policies
  • 11.6.3 Precision Psychiatry Reimbursement Trends

12. Competitive Landscape

• 12.1 Market Structure Analysis
  • 12.1.1 Diagnostic Testing Companies
  • 12.1.2 Genomic Testing Companies
  • 12.1.3 Digital Biomarker Developers
  • 12.1.4 Neurotechnology Companies
• 12.2 Competitive Benchmarking
  • 12.2.1 Technology Platforms
  • 12.2.2 Biomarker Portfolio Analysis
  • 12.2.3 Geographic Presence
  • 12.2.4 Strategic Collaborations
• 12.3 Strategic Developments
  • 12.3.1 Partnerships
  • 12.3.2 Acquisitions
  • 12.3.3 Licensing Agreements
  • 12.3.4 Research Collaborations

13. Company Profiles

• 13.1 Myriad Genetics, Inc.
  • 13.1.1 Company Overview
  • 13.1.2 GeneSight Psychotropic Test
  • 13.1.3 Psychiatric Applications
  • 13.1.4 Pipeline and Innovation Activities
• 13.2 Quest Diagnostics Incorporated
  • 13.2.1 Company Overview
  • 13.2.2 Pharmacogenomic Testing Services
  • 13.2.3 Mental Health Diagnostic Applications
  • 13.2.4 Precision Psychiatry Initiatives
• 13.3 Labcorp Holdings Inc.
  • 13.3.1 Company Overview
  • 13.3.2 Pharmacogenomic Testing Portfolio
  • 13.3.3 Psychiatric Biomarker Applications
• 13.4 F. Hoffmann-La Roche Ltd.
  • 13.4.1 Company Overview
  • 13.4.2 Molecular Diagnostics Portfolio
  • 13.4.3 Neuropsychiatric Biomarker Research
• 13.5 Illumina, Inc.
  • 13.5.1 Company Overview
  • 13.5.2 Sequencing Technologies
  • 13.5.3 Psychiatric Genetics Applications
• 13.6 Thermo Fisher Scientific Inc.
  • 13.6.1 Company Overview
  • 13.6.2 Genomic and Proteomic Platforms
  • 13.6.3 Biomarker Discovery Applications
• 13.7 Bio-Rad Laboratories, Inc.
  • 13.7.1 Company Overview
  • 13.7.2 Molecular Diagnostics Technologies
  • 13.7.3 Biomarker Validation Applications
• 13.8 NeoGenomics, Inc.
  • 13.8.1 Company Overview
  • 13.8.2 Advanced Molecular Testing Capabilities
  • 13.8.3 Biomarker Research Applications
• 13.9 Eurofins Scientific SE
  • 13.9.1 Company Overview
  • 13.9.2 Specialty Diagnostic Services
  • 13.9.3 Biomarker Validation Activities
• 13.10 Natera, Inc.
  • 13.10.1 Company Overview
  • 13.10.2 Molecular Diagnostics Platform
  • 13.10.3 Research and Biomarker Development Activities

14. Future Outlook

• 14.1 Market Evolution Outlook
  • 14.1.1 Precision Psychiatry Adoption
  • 14.1.2 Biomarker-Guided Treatment Selection
  • 14.1.3 Digital Psychiatry Integration
• 14.2 Innovation Outlook
  • 14.2.1 Multi-Omics Biomarker Platforms
  • 14.2.2 AI-Based Mental Health Diagnostics
  • 14.2.3 Digital Biomarker Expansion
• 14.3 Strategic Recommendations
  • 14.3.1 Diagnostic Developers
  • 14.3.2 Healthcare Providers
  • 14.3.3 Investors
  • 14.3.4 Research Institutions

15. Methodology

• 15.1 Research Framework
• 15.2 Primary Research Methodology
• 15.3 Secondary Research Methodology
• 15.4 Epidemiology Modeling Methodology
• 15.5 Market Forecasting Methodology
• 15.6 Data Validation Framework
• 15.7 Assumptions and Limitations
• 15.8 Data Sources
  • 15.8.1 FDA
  • 15.8.2 EMA / IVDR
  • 15.8.3 PMDA
  • 15.8.4 CDSCO
  • 15.8.5 NMPA
  • 15.8.6 ClinicalTrials.gov
  • 15.8.7 Peer-Reviewed Publications
  • 15.8.8 Company Annual Reports and Filings
• 15.9 Abbreviations and Definitions